ERIK KOMENDANT

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

H.R. 1262

Mikaela Naylon Give Kids a Chance Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Original LDA source filings (92)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2026 · second_quarter · 2T

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

PHA

Pharmacy

Issues related to prescription drug pricing.

CPT

Issues related to prescription drug pricing.

HCR

Health Issues

Issues related to prescription drug pricing.

Source: Senate LDA

Show 96 more cited filings

PARA–EMT Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

PARA–EMT Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

Protecting Access to Ground Ambulance Medical Services Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

Protecting Access to Ground Ambulance Medical Services Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

H.R. 2477

Portable Ultrasound Reimbursement Equity Act of 2025

Client: TRIDENTCARE · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to Medicare reimbursement levels, portable x-ray services and ultrasounds for long-term care residents. Issues related to clinical laboratory and x-ray technician staffing shortages. Issues related to HR. 2477, the Portable Ultrasound Reimbursement Equity (PURE) Act. Issues related to S. 1168, the Portable Ultrasound Reimbursement Equity (PURE) Act.

H.R. 2477

Portable Ultrasound Reimbursement Equity Act of 2025

Client: TRIDENTCARE · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to Medicare reimbursement levels, portable x-ray services and ultrasounds for long-term care residents. Issues related to clinical laboratory and x-ray technician staffing shortages. Issues related to HR. 2477, the Portable Ultrasound Reimbursement Equity (PURE) Act. Issues related to S. 1168, the Portable Ultrasound Reimbursement Equity (PURE) Act.

H.R. 2538

CARE Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

H.R. 2538

CARE Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

H.R. 3010

No Handouts for Drug Advertisements Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

H.R. 3010

No Handouts for Drug Advertisements Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

H.R. 3152

Patent Eligibility Restoration Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 3152

Patent Eligibility Restoration Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 3160

PREVAIL Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 3160

PREVAIL Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 3269

ETHIC Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 3269

ETHIC Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 3789

DTC Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

H.R. 3789

DTC Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

H.R. 3838

Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client: GHOSTWORKS MARINE · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R.3838, the Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026.

H.R. 3838

Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client: GHOSTWORKS MARINE · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R.3838, the Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026.

H.R. 4011

Community Paramedicine Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

H.R. 4011

Community Paramedicine Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

H.R. 4570

Interagency Patent Coordination and Improvement Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 4570

Interagency Patent Coordination and Improvement Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 5526

Biosimilar Red Tape Elimination Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

H.R. 5526

Biosimilar Red Tape Elimination Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

H.R. 6485

Skinny Labels, Big Savings Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 6485

Skinny Labels, Big Savings Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

H.R. 7277

Emergency Medical Services Reimbursement for On-Scene and Support Act

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

H.R. 7277

Emergency Medical Services Reimbursement for On-Scene and Support Act

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 1032

Major Richard Star Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1032

Major Richard Star Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1040

Drug Competition Enhancement Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1040

Drug Competition Enhancement Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1041

Affordable Prescriptions for Patients Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1041

Affordable Prescriptions for Patients Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1095

Stop STALLING Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1095

Stop STALLING Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1096

Preserve Access to Affordable Generics and Biosimilars Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1096

Preserve Access to Affordable Generics and Biosimilars Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1097

Interagency Patent Coordination and Improvement Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1097

Interagency Patent Coordination and Improvement Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1168

Portable Ultrasound Reimbursement Equity Act of 2025

Client: TRIDENTCARE · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to Medicare reimbursement levels, portable x-ray services and ultrasounds for long-term care residents. Issues related to clinical laboratory and x-ray technician staffing shortages. Issues related to HR. 2477, the Portable Ultrasound Reimbursement Equity (PURE) Act. Issues related to S. 1168, the Portable Ultrasound Reimbursement Equity (PURE) Act.

S. 1168

Portable Ultrasound Reimbursement Equity Act of 2025

Client: TRIDENTCARE · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to Medicare reimbursement levels, portable x-ray services and ultrasounds for long-term care residents. Issues related to clinical laboratory and x-ray technician staffing shortages. Issues related to HR. 2477, the Portable Ultrasound Reimbursement Equity (PURE) Act. Issues related to S. 1168, the Portable Ultrasound Reimbursement Equity (PURE) Act.

S. 1414

Expedited Access to Biosimilars Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1414

Expedited Access to Biosimilars Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1533

A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physicians for disability examinations, and for other purposes.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1533

A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physicians for disability examinations, and for other purposes.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1546

Patent Eligibility Restoration Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1546

Patent Eligibility Restoration Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 1643

Protecting Access to Ground Ambulance Medical Services Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 1643

Protecting Access to Ground Ambulance Medical Services Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 1785

No Handouts for Drug Advertisements Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

S. 1785

No Handouts for Drug Advertisements Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

S. 1954

Biosimilar Red Tape Elimination Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 1954

Biosimilar Red Tape Elimination Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 2276

ETHIC Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 2276

ETHIC Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 229

DTC Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

S. 229

DTC Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

S. 2630

Saving NSF’s Workforce Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 2630

Saving NSF’s Workforce Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 2658

Medication Affordability and Patent Integrity Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 2658

Medication Affordability and Patent Integrity Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 3014

Ensuring Timely Access to Generics Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 3014

Ensuring Timely Access to Generics Act of 2025

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

S. 3145

CARE Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 3145

CARE Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 3730

Emergency Medical Services Reimbursement for On-Scene Care and Support Act

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 3730

Emergency Medical Services Reimbursement for On-Scene Care and Support Act

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

S. 43

Skinny Labels, Big Savings Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

S. 43

Skinny Labels, Big Savings Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Lower Energy Costs Act

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to geosynthetic containment solutions for the energy industry. Issues related to energy and environmental permitting reform. Issues related to Buy America. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the creation of the Geosynthetics Caucus.

Lower Energy Costs Act

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to geosynthetic containment solutions for the energy industry. Issues related to energy and environmental permitting reform. Issues related to Buy America. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the creation of the Geosynthetics Caucus.

For the People Act of 2021

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

For the People Act of 2021

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

Infrastructure Investment and Jobs Act

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to promoting the use of geosynthetic materials in civil infrastructure, including aviation infrastructure. Issues related to the implementation of H.R. 3684, the the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to surface transportation reauthorization. Issues related to the Geosynthetic Materials Caucus.

Infrastructure Investment and Jobs Act

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

Infrastructure Investment and Jobs Act

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

Infrastructure Investment and Jobs Act

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to promoting the use of geosynthetic materials in civil infrastructure, including aviation infrastructure. Issues related to the implementation of H.R. 3684, the the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to surface transportation reauthorization. Issues related to the Geosynthetic Materials Caucus.

Inflation Reduction Act of 2022

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to promoting the use of geosynthetic materials in civil infrastructure, including aviation infrastructure. Issues related to the implementation of H.R. 3684, the the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to surface transportation reauthorization. Issues related to the Geosynthetic Materials Caucus.

Inflation Reduction Act of 2022

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

Inflation Reduction Act of 2022

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

Inflation Reduction Act of 2022

Client: GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to promoting the use of geosynthetic materials in civil infrastructure, including aviation infrastructure. Issues related to the implementation of H.R. 3684, the the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to surface transportation reauthorization. Issues related to the Geosynthetic Materials Caucus.

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025. Issues related to H.R. 1, One Big Beautiful Bill Act.

H.R. 1262

Mikaela Naylon Give Kids a Chance Act

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act.

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act.

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act.

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Client: CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

PARA–EMT Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

PARA–EMT Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to the Community Paramedicine Act of 2024. Issues related to the Supporting Our First Responders Act. Issues related to H.R.3443. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

PARA–EMT Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to the Community Paramedicine Act of 2024. Issues related to the Supporting Our First Responders Act. Issues related to the EMS Counts Act of 2023. Issues related to H.R. 2220, the PARA-EMT Act of 2025.

PARA–EMT Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

Protecting Access to Ground Ambulance Medical Services Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

Protecting Access to Ground Ambulance Medical Services Act of 2025

Client: SARNOVA, LLC · Firm: WHITMER & WORRALL, LLC

Cited source text

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to the Community Paramedicine Act of 2024. Issues related to the Supporting Our First Responders Act. Issues related to H.R.3443. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

Show 88 more original filings

2026 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues surrounding tariffs on EMS and pharmaceutical industry products, including medical supplies.

HCR

Health Issues

Issues related to H.R. 2538 & S. 3145, the CARE Act of 2025. Issues related to H.R. 7277 & S. 3730, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2026 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Medicare reimbursement levels, portable x-ray services and ultrasounds for long-term care residents. Issues related to clinical laboratory and x-ray technician staffing shortages. Issues related to HR. 2477, the Portable Ultrasound Reimbursement Equity (PURE) Act. Issues related to S. 1168, the Portable Ultrasound Reimbursement Equity (PURE) Act.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

ENV

Environment/Superfund

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.

TRA

Transportation

Issues related to promoting the use of geosynthetic materials in civil infrastructure, including aviation infrastructure. Issues related to the implementation of H.R. 3684, the the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to surface transportation reauthorization. Issues related to the Geosynthetic Materials Caucus.

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

PHA

Pharmacy

Issues related to prescription drug pricing.

CPT

Issues related to prescription drug pricing.

HCR

Health Issues

Issues related to prescription drug pricing.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

MMM

Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

TAX

Taxation/Internal Revenue Code

S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.

PHA

Pharmacy

Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act

2026 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

TRA

Transportation

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to the fast ferries programs. Issues related to ATTAIN grants. Issues related to port infrastructure. Issues related to FTA ferry grant projects. Issues related to surface transportation reauthorization.

BUD

Budget/Appropriations

Issues related to the Department of Defense Appropriations Act, 2027. Issues related to the Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027. Issues related to the Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2027. Issues related to the Department of Homeland Security Appropriations Act, 2027.

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues surrounding tariffs on EMS and pharmaceutical industry products, including medical supplies.

HCR

Health Issues

Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2026 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2026 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRA

Transportation

ENV

Environment/Superfund

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2025 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to prescription drug pricing.

CPT

Issues related to prescription drug pricing.

PHA

Pharmacy

Issues related to prescription drug pricing.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2025 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

MMM

Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.

CPT

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

PHA

2025 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

BUD

Budget/Appropriations

Issues related to S. 2572 and H.R. 4016, the Department of Defense Appropriations Act, 2026. Issues related to H.R.5342 and S. 2354, the Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026. Issues related to H.R. 4552 and S. 2465, the Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2026. Issues related to H.R. 4213, the Department of Homeland Security Appropriations Act, 2026.

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

MAR

Marine/Maritime/Boating/Fisheries

2025 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 4011, the Community Paramedicine Act of 2025. Issues related to the Supporting Our First Responders Act. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

TRD

Trade (domestic/foreign)

Issues surrounding tariffs on EMS and pharmaceutical industry products, including medical supplies.

Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2025 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

ENG

Energy/Nuclear

Issues related to geosynthetic containment solutions for the energy industry. Issues related to energy and environmental permitting reform. Issues related to Buy America. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the creation of the Geosynthetics Caucus.

ENV

Environment/Superfund

TRA

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2025 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to prescription drug pricing.

CPT

Issues related to prescription drug pricing.

PHA

Pharmacy

Issues related to prescription drug pricing.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2025 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025. Issues related to H.R. 1, One Big Beautiful Bill Act.

CPT

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. S.43 Skinny Labels, Big Savings Act. H.R. 5526/S. 1954, the Biosimilar Red Tape Elimination Act. S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

2025 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

MAR

Marine/Maritime/Boating/Fisheries

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to fast ferries programs.

TRA

Transportation

ENG

Energy/Nuclear

2025 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

TRD

Trade (domestic/foreign)

Issues surrounding tariffs on EMS and pharmaceutical industry products, including medical supplies.

Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2025 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRA

Transportation

ENG

Energy/Nuclear

ENV

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2025 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to prescription drug pricing.

CPT

Issues related to prescription drug pricing.

PHA

Pharmacy

Issues related to prescription drug pricing.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2025 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Issues related to prescription drug prices. S.1041 Affordable Prescriptions for Patients Act. Fair Accountability and Innovative Research Drug Pricing Act. S.229 Drug Price Transparency for Consumers Act.

CPT

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act H.R. 3160 & S. 1533, the PREVAIL Act S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025 S.43 Skinny Labels, Big Savings Act S. 1954, the Biosimilar Red Tape Elimination Act S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act S.1040 Drug Competition Enhancement Act

PHA

2025 · second_quarter · Q2

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

BUD

Budget/Appropriations

Issues related to H.R. 8752, the Department of Defense Appropriations Act, 2025. Issues related to the Commerce, Justice, and Science, Interior and Environment, and Energy and Water Development Appropriations Act, 2025. Issues related to the Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025. Issues related to H.R. 8752, the Department of Homeland Security Appropriations Act, 2025.

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

MAR

Marine/Maritime/Boating/Fisheries

2025 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to the Community Paramedicine Act of 2024. Issues related to the Supporting Our First Responders Act. Issues related to H.R.3443. Issues related to H.R. 2220, the PARA-EMT Act of 2025. Issues related to H.R. 2232 & S. 1643, Protecting Access to Ground Ambulance Medical Services Act of 2025.

TRD

Trade (domestic/foreign)

Issues surrounding tariffs on EMS and pharmaceutical industry products, including medical supplies.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2025 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRA

Transportation

ENG

Energy/Nuclear

ENV

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2025 · second_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Issues related to prescription drug prices

CPT

Issues related to prescription drug prices

PHA

Pharmacy

Issues related to prescription drug prices

2025 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

CPT

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act Patent Eligibility Restoration Act PREVAIL Act S.5573 A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43 Skinny Labels, Big Savings Act S.1040 Drug Competition Enhancement Act

PHA

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2025 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

2025 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

BUD

Budget/Appropriations

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

MAR

Marine/Maritime/Boating/Fisheries

2025 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to H.R. 2538, the CARE Act of 2025. Issues related to the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to the Community Paramedicine Act of 2024. Issues related to the Supporting Our First Responders Act. Issues related to the EMS Counts Act of 2023. Issues related to H.R. 2220, the PARA-EMT Act of 2025.

BUD

Budget/Appropriations

Workforce issues related to FY25 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2025 · first_quarter · Q1

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2025 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

TRA

Transportation

ENG

Energy/Nuclear

ENV

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2024 · third_quarter · 3A

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

MAR

Marine/Maritime/Boating/Fisheries

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to fast ferries program.

TRA

Transportation

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to the fast ferries program. Issues related to ATTAIN grants. Issues related to port infrastructure. Issues related to FTA ferry grant projects.

DEF

Defense

Issues related to H. R. 8070, the Servicemember Quality of Life Improvement Act and National Defense Authorization Act for Fiscal Year 2025.

2024 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Issues related to prescription drug prices. S.150/H.R.9070 Affordable Prescriptions for Patients Act. S.935 Fair Accountability and Innovative Research Drug Pricing Act. S.1250/H.R.5958 Drug Price Transparency for Consumers Act.

PHA

Pharmacy

Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act. H.R.10545, the American Relief Act.

CPT

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2024 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

2024 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

MAR

Marine/Maritime/Boating/Fisheries

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to fast ferries program.

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

BUD

Budget/Appropriations

Issues related to H.R. 4367, the Department of Homeland Security Appropriations Act, 2024. Issues related to S. 2625, the Department of Homeland Security Appropriations Act, 2024. Issues related to H.R. 4365, the Department of Defense Appropriations Act, 2024. Issues related to S. 2587, the Department of Defense Appropriations Act, 2024. Issues related to the House FY24 Commerce, Justice, Science, and Related Agencies Appropriations Act. Issues relared to S. 2321, the Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024. Issues related to the House FY24 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act. Issues related to S. 2624, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024. H.R. 2882 - Further Consolidated Appropriations Act, 2024 Issues related to H.R. 8752, the Department of Defense Appropriations Act, 2025. Issues related to the Commerce, Justice, and Science, Interior and Environment, and Energy and Water Development Appropriations Act, 2025. Issues related to the Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025. Issues related to H.R. 8752, the Department of Homeland Security Appropriations Act, 2025.

2024 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Medicare reimbursement levels, portable x-ray services and ultrasounds for long-term care residents. Issues related to the Provider Relief Fund. Issues related to clinical laboratory and x-ray technician staffing shortages. Issues related to HR. 10240, the Portable Ultrasound Reimbursement Equity (PURE) Act. Issues related to S. 5380, the Portable Ultrasound Reimbursement Equity (PURE) Act.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2024 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Workforce issues related to FY25 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act

HCR

Health Issues

Issues related to H.R. 8977, the Improving Access to Emergency Medical Services Act of 2024. Issues related to S. 3236/ H.R. 6257, the Emergency Medical Services Reimbursement for On-Scene Care and Support Act. Issues related to H.R. 8042, the Community Paramedicine Act of 2024. Issues related to H.R. 1737, Supporting Our First Responders Act. Issues related to H.R. 4646/ S. 265, the SIREN Reauthorization Act. Issues related to S. 1115, the EMS Counts Act of 2023. Issues related to H.R. 6140, the FAST PASS Act. Issues related to H.R. 6433, the PARA-EMT Act of 2023. Issues related to H.R. 1666/ S. 1673, Protecting Access to Ground Ambulance Medical Services Act of 2023. Issues related to S. 5400, Improving Access to Emergency Medical Services Act.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2024 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

ENG

Energy/Nuclear

ENV

Environment/Superfund

TRA

CARELINK HOME HEALTH via WHITMER & WORRALL, LLC

2024 · fourth_quarter · 4T

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Medicare provider enrollment and revalidation.

Filing targets: Centers For Medicare and Medicaid Services (CMS)

CARELINK HOME HEALTH via WHITMER & WORRALL, LLC

2024 · third_quarter · 3A

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Medicare provider enrollment and revalidation.

Filing targets: Centers For Medicare and Medicaid Services (CMS)

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2024 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2024 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Issues related to prescription drug prices. S.150 Affordable Prescriptions for Patients Act. S.935 Fair Accountability and Innovative Research Drug Pricing Act. S.1250/H.R.5958 Drug Price Transparency for Consumers Act.

CPT

Patent abuse issues. S. 150 Affordable Prescriptions for Patients Act of 2023. S. 79 Interagency Patent Coordination Act. S. 2780 Medication Affordability and Patent Integrity Act S. 142 Preserve Access to Affordable Generics and Biosimilars Act Joint USPTO-FDA Collaboration Initiatives. S. 2140 Patent Eligibility Restoration Act of 2023 S. 2220 PREVAIL Act S. 3583 A bill to address patent thickets. H.R. 6986 To address patent thickets.

PHA

UNIVERSITY OF CENTRAL FLORIDA via WHITMER & WORRALL, LLC

2024 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

TRA

Transportation

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to the fast ferries program. Issues related to ATTAIN grants. Issues related to port infrastructure. Issues related to FTA ferry grant projects.

MAR

Marine/Maritime/Boating/Fisheries

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to fast ferries program.

BUD

Budget/Appropriations

2024 · third_quarter · 3T

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (7 issues)

SCI

Science/Technology

Issues related to the implementation of H.R. 4346, the Chips and Science Act. Issues related to the National Science Foundation (NSF)'s Regional Innovative Engines competition. Issues related to the Congressional Planetary Science Caucus. Issues related to the Congressional Modeling & Simulation Caucus. Issues related to the Congressional Optics & Photonics Caucus.

BUD

Budget/Appropriations

Issues related to the Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025. Issues related to the Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025. Issues related to H.R. 8774, the Department of Defense Appropriations Act, 2025. Issues related to H.R. 9029, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025.

HCR

2024 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

BUD

Budget/Appropriations

Workforce issues related to FY25 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2024 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2024 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

ENG

Energy/Nuclear

ENV

Environment/Superfund

TRA

CARELINK HOME HEALTH via WHITMER & WORRALL, LLC

2024 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Assist with Medicare provider enrollment and revalidation.

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2024 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2024 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

PHA

Pharmacy

MMM

Medicare/Medicaid

CPT

UNIVERSITY OF CENTRAL FLORIDA via WHITMER & WORRALL, LLC

2024 · second_quarter · Q2

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

BUD

Budget/Appropriations

ENG

2024 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (7 issues)

DEF

Defense

Issues related to advancing the U.S. optics and photonics industry. Issues related to modeling and simulation. Issues related to the Congressional Modeling and Simulation Caucus. Issues related to the Congressional Optics and Photonics Caucus. Issues related to H.R. 2670, National Defense Authorization Act for Fiscal Year 2024. Issues related to S. 2226, the National Defense Authorization Act for Fiscal Year 2024. Issues related to hypersonics. Issues related to high energy lasers. Issues related to H. R. 8070, the Servicemember Quality of Life Improvement Act and National Defense Authorization Act for Fiscal Year 2025.

TRA

Transportation

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to transportation research opportunities. Issues related to wrong way driving technology.

2024 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Workforce issues related to FY25 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act

HCR

Health Issues

Issues related to the implementation of H.R. 1319, the American Rescue Plan Act of 2021. Issues related to H.R. 1609 / S.149, the Treatment in Place Act. Issues related to H.R. 3635 / S. 1974, the Strengthening America's Strategic National Stockpile Act of 2021. Issues related to the EMS workforce. Issues related to EMS funding. Issues related to H.R. 1737, the Supporting Our First Responders Act. Issues related to the Congressional EMS Caucus. Issues related to the Bipartisan Pandemic Preparedness Caucus. Issues related to H.R. 1012, the Cardiac Arrest Survival Act of 2023.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2024 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2024 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

AVI

Aviation/Airlines/Airports

Issues related to promoting the use of geosynthetic materials in aviation infrastructure. Issues related to H.R. 3935, the Securing Growth and Robust Leadership in American Aviation Act. Issues related to S. 1939, the FAA Reauthorization Act of 2023. Issues related to Airfield Pavement Technology Program (APTP).

ENV

Environment/Superfund

ENG

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2024 · second_quarter · 2T

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

DEF

Defense

Issues related to PFAS contamination on certain military base installations. Issues related to the National Defense Authorization Act for Fiscal Year 2025.

ENV

Environment/Superfund

Issues related to water reuse and Buy America issues. Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to PFAS liability. Issues related to S. 1430, the Water Systems PFAS Liability Protection Act. Issues related to H.R. 7944, the Water Systems PFAS Liability Protection Act. Issues related to H.R. 3490, the Water Infrastructure Modernization Act of 2023.

TRA

2024 · first_quarter · Q1

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CPT

PHA

Pharmacy

MMM

UNIVERSITY OF CENTRAL FLORIDA via WHITMER & WORRALL, LLC

2024 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

ENV

Environment/Superfund

TRA

Transportation

Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to PFAS treatment for contaminated water, water re-use, Buy America, and other water remediation issues.

DEF

2024 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (7 issues)

BUD

Budget/Appropriations

HCR

Health Issues

Issues related to the future of digital health.

2024 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to Medicare reimbursement levels and portable x-ray services for long-term care residents. Issues related to the Provider Relief Fund. Issues related to clinical laboratory and x-ray technician staffing shortages.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2024 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

Workforce issues related to H.R. 5894 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2624 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2024 · first_quarter · Q1

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

MAR

Marine/Maritime/Boating/Fisheries

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to fast ferries program.

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

TRA

Transportation

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to the fast ferries program. Issues related to ATTAIN grants. Issues related to port infrastructure.

2024 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

UNIVERSITY OF CENTRAL FLORIDA via WHITMER & WORRALL, LLC

2023 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

TRA

Transportation

BUD

Budget/Appropriations

Issues related to H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024. Issues related to S. 2127, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024. Issues related to H.R. 4365, the Department of Defense Appropriations Act, 2024. Issues related to S. 2587, the Department of Defense Appropriations Act, 2024. Issues related to H.R. 4394, the Energy and Water Development and Related Agencies Appropriations Act, 2024. Issues related to S. 2443, the Energy and Water Development and Related Agencies Appropriations Act, 2024. Issues related to H.R. 4821, the Department of the Interior, Environment, and Related Agencies Appropriations Act, 2024. Issues related to S. 2605, the Department of the Interior, Environment, and Related Agencies Appropriations Act, 2024.

2023 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (7 issues)

SPO

Sports/Athletics

Issues related to name image likeness (NIL) legislation.

DEF

Defense

BUD

Budget/Appropriations

2023 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2023 · fourth_quarter · Q4

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ROTECH HEALTHCARE INC. via WHITMER & WORRALL, LLC

2023 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the home healthcare equipment market. Issues related to Medicare reimbursement levels. Issues related to CMS and DME rulemaking. Issues related to competitive bidding reform. Issues related to including non-invasive ventilators in the Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) competitive acquisition program. Issues related to audits imposed on the home healthcare equipment industry. Issues related to the S. 1229, the Supplemental Oxygen Access Reform (SOAR) Act. Issues related to creating an electronic template for the Durable Medical Equipment (DME) industry. Issues related to H.R. 5555, the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Relief Act of 2023. Issues related to S. 1294, the Competitive Bidding Relief Act of 2023.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GEOSYNTHETIC MATERIALS ASSOCIATION - ATA (FORMERLY KNOWN AS GMA - IFAI) via WHITMER & WORRALL, LLC

2023 · fourth_quarter · Q4

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

HOM

Homeland Security

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies.

MAR

Marine/Maritime/Boating/Fisheries

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to ice breaking technologies. Issues related to fast ferries program.

BUD

Budget/Appropriations

Issues related to homeland security, transportation, and innovative marine vessel design and capabilities. Issues related to H.R. 4367, the Department of Homeland Security Appropriations Act, 2024. Issues related to S. 2625, the Department of Homeland Security Appropriations Act, 2024. Issues related to ice breaking technologies.

2023 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

AVI

Aviation/Airlines/Airports

TRA

Transportation

Issues related to promoting the use of geosynthetic materials in civil infrastructure, including aviation infrastructure. Issues related to the implementation of H.R. 3684, the the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022. Issues related to the implementation of the Water Resources Development Act of 2022 in H.R. 7776, the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023.

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2023 · fourth_quarter · 4A

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2023 · fourth_quarter · Q4

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostics testing.

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2023 · fourth_quarter · Q4

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

PHA

Pharmacy

CPT

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2023 · fourth_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostic tests.

EUROFINS TRANSPLANT GENOMICS INC. via WHITMER & WORRALL, LLC

2023 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to CMS coverage of molecular diagnostic tests.

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) via WHITMER & WORRALL, LLC

2023 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

CPT

Issues related to prescription drug prices. S.150 Affordable Prescriptions for Patients Act

MMM

Medicare/Medicaid

Issues related to prescription drug prices. S.150 Affordable Prescriptions for Patients Act

UNIVERSITY OF CENTRAL FLORIDA via WHITMER & WORRALL, LLC

2023 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

BUD

Budget/Appropriations

DEF

Defense

Issues related to PFAS contamination on certain military base installations. Issues related to H.R. 2670, the National Defense Authorization Act for Fiscal Year 2024. Issues related to S. 2226, the National Defense Authorization Act for Fiscal Year 2024.

2023 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (7 issues)

HCR

Health Issues

Issues related to the future of digital health.

EDU

Education

Issues related to higher education. Issues related to the implementation of H.R. 4346, the Chips and Science Act. Issues related to S. 1795, the Fairness in Higher Education Accreditation Act. Issues related to Hispanic Serving Institutions (HSI).

TRA

Transportation

2023 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE